Glucocorticoid-induced osteoporosis in rheumatic diseases
Clinics
;
65(11): 1197-1205, 2010. tab
Artigo
em Inglês
| LILACS
| ID: lil-571436
ABSTRACT
The aim of this article is to review rheumatological diseases that are associated with glucocorticoid-induced osteoporosis or fractures and to perform a critical analysis of the current guidelines and treatment regimens. The electronic database MEDLINE was searched using the date range of July 1986 to June 2009 and the following search terms osteoporosis, bone mineral density, fractures, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, vasculitis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis and juvenile dermatomyositis. Osteopenia and osteoporosis respectively account for 1.4 to 68.7 percent and 5.0 to 61.9 percent of adult rheumatological diseases. Among juvenile rheumatological disorders, the frequency of low bone mass ranges from 38.7 to 70 percent. In general, fracture rates vary from 0 to 25 percent. Although glucocorticoid-induced osteoporosis has a high rate of prevalence among rheumatic diseases, a relatively low number of patients on continuous glucocorticoid treatment receive adequate diagnostic evaluation or preventive therapy. This deficit in patient care may result from a lack of clear understanding of the attributed risks by the patients and physicians, the high complexity of the treatment guidelines and poor patient compliance.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Osteoporose
/
Doenças Reumáticas
/
Glucocorticoides
Tipo de estudo:
Guia de Prática Clínica
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Clinics
Assunto da revista:
Medicina
Ano de publicação:
2010
Tipo de documento:
Artigo
/
Documento de projeto
Similares
MEDLINE
...
LILACS
LIS